Ibrance w/ Faslodex Improves Overall Survival in Advanced HR+BC

Moderators
Moderators Member Posts: 25,912

Adding Ibrance to Faslodex Improves Overall Survival in Advanced-Stage, Hormone-Receptor-Positive Breast Cancer
October 24, 2018

Latest results from the PALOMA-3 trial show adding Ibrance to Faslodex improves overall survival by about 7 months compared to Faslodex alone in women diagnosed with hormone-receptor-positive, HER2-negative advanced-stage breast cancer that had grown while being treated with hormonal therapy. Read more...

Categories